Home/Filings/4/A/0001753926-24-001139
4/A//SEC Filing

Francis Knuettel II 4/A

Accession 0001753926-24-001139

CIK 0001919246other

Filed

Jun 17, 8:00 PM ET

Accepted

Jun 18, 8:07 PM ET

Size

6.1 KB

Accession

0001753926-24-001139

Insider Transaction Report

Form 4/AAmended
Period: 2024-02-21
Francis Knuettel II
CFO, Treas & Secty
Transactions
  • Award

    Employee Stock Option

    2024-02-21+2,77825,001 total(indirect: By LLC)
    Exercise: $22.68From: 2024-02-21Exp: 2033-01-10Common Stock (2,778 underlying)
Footnotes (2)
  • [F1]On February 23, 2024, the Reporting Person filed a Form 4 which inadvertently reported that, Camden Capital LLC disposed of 2,778 shares of the Issuer's common stock. In fact, following the grant of stock options to Camden Capital LLC, it acquired 2,778 shares of the Issuer's common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering.
  • [F2]The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.

Documents

1 file

Issuer

Chromocell Therapeutics Corp

CIK 0001919246

Entity typeother

Related Parties

1
  • filerCIK 0001433316

Filing Metadata

Form type
4/A
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 8:07 PM ET
Size
6.1 KB